Astrazeneca FY2026 EPS Estimate Lifted by Erste Group Bank

Astrazeneca Plc (NYSE:AZN) – Research analysts at Erste Group Bank raised their FY2026 earnings per share estimates for shares of Astrazeneca in a research report issued on Friday, September 18th. Erste Group Bank analyst H. Engel now expects that the company will earn $10.34 per share for the year, up from their previous estimate of $10.17. The consensus estimate for Astrazeneca’s current full-year earnings is $9.34 per share. Erste Group Bank also issued estimates for Astrazeneca’s FY2027 earnings at $11.50 EPS.

Astrazeneca (NYSE:AZN) last released its earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. The company had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The business’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period last year, the firm earned $2.17 EPS.

AZN has been the subject of several other reports. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Zacks Research cut shares of Astrazeneca from a “hold” rating to a “strong sell” rating in a research report on Monday, September 14th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Bank of America restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and an average price target of $206.67.

Astrazeneca Trading Up 1.2%

Shares of AZN opened at $168.15 on Tuesday. The stock’s fifty day simple moving average is $164.03 and its 200-day simple moving average is $180.13. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $260.79 billion, a PE ratio of 25.13, a price-to-earnings-growth ratio of 1.41 and a beta of 0.25. Astrazeneca has a 12-month low of $145.79 and a 12-month high of $212.71.

Institutional Trading of Astrazeneca

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Premier Financial Group bought a new stake in shares of Astrazeneca in the 2nd quarter valued at $71,000. Tidal Investments LLC lifted its holdings in Astrazeneca by 14.5% during the second quarter. Tidal Investments LLC now owns 248,108 shares of the company’s stock worth $46,554,000 after acquiring an additional 31,379 shares in the last quarter. Archford Capital Strategies LLC acquired a new position in Astrazeneca in the second quarter valued at about $498,000. Cidel Asset Management Inc. acquired a new position in Astrazeneca in the second quarter valued at about $44,480,000. Finally, Capital Analysts LLC increased its holdings in shares of Astrazeneca by 18.2% in the second quarter. Capital Analysts LLC now owns 962 shares of the company’s stock worth $181,000 after acquiring an additional 148 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Enhertu secured NHS funding in England. AstraZeneca and Daiichi Sankyo’s breast-cancer drug was cleared for use by England’s National Health Service in patients with HER2-low metastatic breast cancer. The decision reverses an earlier cost-effectiveness rejection and expands potential patient access in a major European market. AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
• Positive Sentiment: European regulators recommended two AstraZeneca treatments. The European Medicines Agency’s CHMP issued positive opinions for Enhertu and Klygefa. Klygefa’s recommendation covers AChR-positive generalized myasthenia gravis and is supported by Phase III data, while Enhertu’s recommendation could broaden its European oncology opportunity. AstraZeneca’s Enhertu, Klygefa Get Positive CHMP Opinions in EU
• Positive Sentiment: Efzimfotase alfa received FDA priority review. The designation for the hypophosphatasia treatment could accelerate the U.S. regulatory timetable and improve visibility for a potential rare-disease product launch. FDA Grants Priority Review to AstraZeneca’s Efzimfotase Alfa
• Positive Sentiment: Erste Group Bank raised its earnings forecasts. The bank increased its FY2026 EPS estimate to $10.34 from $10.17 and its FY2027 estimate to $11.50 from $11.44. Both forecasts are above the cited full-year consensus estimate of $9.34, signaling greater confidence in AstraZeneca’s earnings outlook.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.

The company’s portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease.